Q3 2024 EPS Estimates for Jazz Pharmaceuticals plc Boosted by Analyst (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) - Zacks Research lifted their Q3 2024 earnings per share (EPS) estimates for shares of Jazz Pharmaceuticals in a research note issued to investors on Wednesday, August 21st. Zacks Research analyst S. Ganoria now forecasts that the specialty pharmaceutical company will post earnings per share of $4.34 for the quarter, up from their previous forecast of $4.25. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $15.31 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals' Q4 2024 earnings at $4.83 EPS, FY2024 earnings at $15.71 EPS, Q1 2025 earnings at $3.13 EPS, Q2 2025 earnings at $4.08 EPS, Q3 2025 earnings at $4.34 EPS, Q4 2025 earnings at $4.53 EPS, FY2025 earnings at $16.07 EPS, Q1 2026 earnings at $3.75 EPS, Q2 2026 earnings at $4.30 EPS and FY2026 earnings at $17.58 EPS.

Several other research firms also recently weighed in on JAZZ. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a research report on Monday, August 19th. UBS Group cut their target price on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 2nd. Wells Fargo & Company reduced their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating for the company in a report on Thursday, August 1st. Piper Sandler lowered their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an "overweight" rating on the stock in a report on Thursday, August 1st. Finally, The Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a "buy" rating and a $169.00 price objective for the company. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $173.07.

Jazz Pharmaceuticals Trading Up 0.4 %

JAZZ traded up $0.42 during trading on Monday, reaching $114.29. The company had a trading volume of 321,578 shares, compared to its average volume of 667,764. The firm's 50-day simple moving average is $109.10 and its 200 day simple moving average is $112.93. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.90 and a current ratio of 2.37. The company has a market cap of $7.21 billion, a price-to-earnings ratio of 23.56, a PEG ratio of 1.76 and a beta of 0.58. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $146.70.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of JAZZ. Rise Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 203 shares during the last quarter. Versant Capital Management Inc grew its stake in Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after buying an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals in the 2nd quarter worth $29,000. EverSource Wealth Advisors LLC lifted its position in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after acquiring an additional 97 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after acquiring an additional 116 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.